Delcath Systems (NASDAQ:DCTH) Lowered to “Hold” at Zacks Investment Research

Delcath Systems (NASDAQ:DCTH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday, Zacks.com reports.

According to Zacks, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver. “

Shares of NASDAQ DCTH traded up $0.08 during trading on Wednesday, reaching $9.07. The company had a trading volume of 14,353 shares, compared to its average volume of 130,512. Delcath Systems has a 52 week low of $8.28 and a 52 week high of $25.18. The stock has a market cap of $66.72 million, a PE ratio of -2.41 and a beta of 0.53. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.78 and a current ratio of 3.99. The business’s 50 day moving average price is $9.57 and its 200-day moving average price is $10.69.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Monday, August 9th. The company reported ($0.96) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.02. Delcath Systems had a negative net margin of 1,534.53% and a negative return on equity of 166.54%. The company had revenue of $0.54 million during the quarter, compared to analysts’ expectations of $0.40 million. During the same quarter in the previous year, the company earned ($1.90) EPS. Equities analysts anticipate that Delcath Systems will post -3.82 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in the company. Advisory Services Network LLC bought a new position in shares of Delcath Systems in the second quarter worth about $40,000. Goldman Sachs Group Inc. bought a new position in shares of Delcath Systems in the first quarter worth about $125,000. Northern Trust Corp bought a new position in Delcath Systems in the 2nd quarter valued at approximately $161,000. Squarepoint Ops LLC raised its holdings in Delcath Systems by 90.6% in the 2nd quarter. Squarepoint Ops LLC now owns 24,773 shares of the company’s stock valued at $312,000 after buying an additional 11,777 shares during the last quarter. Finally, Millennium Management LLC bought a new position in Delcath Systems in the 2nd quarter valued at approximately $405,000. 21.67% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Read More: Trading Stocks – What are percentage gainers?

Get a free copy of the Zacks research report on Delcath Systems (DCTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.